<DOC>
	<DOCNO>NCT00651274</DOCNO>
	<brief_summary>This study ass whether daily co-administration ezetimibe 10 mg ongoing treatment simvastatin 20 mg effective treatment simvastatin 20 mg alone reduce LDL-C concentration .</brief_summary>
	<brief_title>Comparison Co-administration Ezetimibe Plus Simvastatin Versus Simvastatin Alone Primary Hypercholesterolemia ( P03476 )</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Subjects must demonstrate willingness participate study comply procedure sign write informed consent . Subjects must &gt; = 18 year &lt; = 75 year age . Subjects must LDLC concentration &gt; = 2.6 mmol/L ( 100 mg/dL ) &lt; = 4.1 mmol/L ( 160 mg/dL ) use Friedewald calculation available time randomization Visit 3 ( Baseline Visit ) . Subjects must triglyceride concentration &lt; 3.99 mmol/L ( 350 mg/dL ) Visit 3 ( Baseline Visit ) . Subjects must document coronary heart disease ( CHD ) . For purpose study , CHD include one follow feature : document stable angina ( evidence ischemia exercise test ) ; history myocardial infarction ; history percutaneous coronary intervention ( primarily PTCA without stent placement ) ; symptomatic peripheral vascular disease ( claudication ) ; document history atherothrombotic cerebrovascular disease ; and/or document history unstable angina nonQ wave myocardial infarction . Subject must currently take simvastatin 20 mg daily history take 80 % daily evening dos precede 6 week prior Visit 3 ( Baseline Visit ) . Subjects must liver transaminase ( ALT , AST ) &lt; 50 % upper limit normal , active liver disease , CK &lt; 50 % upper limit normal Visit 3 ( Baseline Visit ) . Clinical laboratory test ( CBC , blood chemistry , urinalysis ) must within normal limit clinically acceptable investigator Visit 3 ( Baseline Visit ) . Subjects must maintain cholesterol lower diet program least 4 week prior study willing continue diet program study . Subjects must report stable weight history least 4 week prior entry study Visit 3 ( Baseline Visit ) . Women receive hormonal therapy , include hormone replacement , estrogen antagonist/agonist , oral contraceptive , must maintain stable dose regimen least 8 week willing continue regimen duration study . Women childbearing potential ( include woman less 1 year postmenopausal woman become sexually active ) must use acceptable method birth control ( e.g. , hormonal contraceptive , medically prescribe IUD , condom combination spermicide ) surgically sterilize ( e.g. , hysterectomy tubal ligation ) . Subjects must free clinically significant disease hyperlipidemia coronary heart disease would interfere study evaluation . Subjects must understand able adhere dose visit schedule , must agree remain cholesterollowering diet exercise regimen duration study . Subjects whose body mass index ( BMI ) &gt; = 30 Kg/m^2 Visit 3 ( Baseline Visit ) . Subjects consume &gt; 14 alcoholic drink per week . ( A drink : beer , glass wine , single measure spirit ) . Any condition situation , opinion investigator , might pose risk subject interfere participation study . Women pregnant nursing . Subjects observed designate washout period prohibit medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>